Abstract
Oseltamivir (has known by its brand name Tamiflu) is a prodrug, requiring ester hydrolysis for conversion to the active form, Oseltamivir carboxylate. Oseltamivir was the first orally active neuraminidase inhibitor commercially developed by US based Gilead Sciences and is currently marketed by F. Hoffmann-La Roche (Roche). Oseltamivir is an antiviral drug which works by blocking the function of the viral neuraminidase protein. US FDA approved Oseltamivir for prophylaxis of uncomplicated influenza A and B. Currently, Oseltamivir is the only first line defense drug available for the treatment of Swine Flu. Orally Oseltamivir is well tolerated and effective in treatment of influenza in adolescents and adults, including the elderly and patients with chronic cardiac and/or respiratory disease. Many of the pharmaceutical companies targeted Oseltamivir as a block buster molecule. In present review, we have tried to cover chemistry, mode of binding, total synthesis, current patent status, adverse effect and clinical status of Oseltamivir giving emphasis on medicinal chemistry aspect.
Keywords: Oseltamivir, tamiflu, neuraminidase inhibitors, swine flu, Oseltamivir carboxylate, active neuraminidase inhibitor, influenza, Influenza A virus subtype H5N1, zanamivir (Relenza), avian flu Pandemic, Peramivir, Oseltamivir phosphate, C16H28N2O4, hemagglutinin, cellular-receptor sialic acid, Glu276 residue, His274Tyr, Patent No. 5,763,483, Patent No. 5,866,601, Patent No. 5,952,375, butadiene, acrylic acid, Prophylaxis of influenza, hepatic esterases, sore throat, live attenuated influ-enza vaccine, P450, glucuronyl transferases, Acetaminophen, Cimetidine, Antacids, aluminum hydroxides, calcium carbonates, Antivirals, Amantadine, Rimantadine
Medicinal Chemistry
Title: Oseltamivir: A First Line Defense Against Swine Flu
Volume: 6 Issue: 4
Author(s): Ritesh Agrawal, Prarthana V. Rewatkar, Ganesh R. Kokil, Arunima Verma and Atin Kalra
Affiliation:
Keywords: Oseltamivir, tamiflu, neuraminidase inhibitors, swine flu, Oseltamivir carboxylate, active neuraminidase inhibitor, influenza, Influenza A virus subtype H5N1, zanamivir (Relenza), avian flu Pandemic, Peramivir, Oseltamivir phosphate, C16H28N2O4, hemagglutinin, cellular-receptor sialic acid, Glu276 residue, His274Tyr, Patent No. 5,763,483, Patent No. 5,866,601, Patent No. 5,952,375, butadiene, acrylic acid, Prophylaxis of influenza, hepatic esterases, sore throat, live attenuated influ-enza vaccine, P450, glucuronyl transferases, Acetaminophen, Cimetidine, Antacids, aluminum hydroxides, calcium carbonates, Antivirals, Amantadine, Rimantadine
Abstract: Oseltamivir (has known by its brand name Tamiflu) is a prodrug, requiring ester hydrolysis for conversion to the active form, Oseltamivir carboxylate. Oseltamivir was the first orally active neuraminidase inhibitor commercially developed by US based Gilead Sciences and is currently marketed by F. Hoffmann-La Roche (Roche). Oseltamivir is an antiviral drug which works by blocking the function of the viral neuraminidase protein. US FDA approved Oseltamivir for prophylaxis of uncomplicated influenza A and B. Currently, Oseltamivir is the only first line defense drug available for the treatment of Swine Flu. Orally Oseltamivir is well tolerated and effective in treatment of influenza in adolescents and adults, including the elderly and patients with chronic cardiac and/or respiratory disease. Many of the pharmaceutical companies targeted Oseltamivir as a block buster molecule. In present review, we have tried to cover chemistry, mode of binding, total synthesis, current patent status, adverse effect and clinical status of Oseltamivir giving emphasis on medicinal chemistry aspect.
Export Options
About this article
Cite this article as:
Agrawal Ritesh, V. Rewatkar Prarthana, R. Kokil Ganesh, Verma Arunima and Kalra Atin, Oseltamivir: A First Line Defense Against Swine Flu, Medicinal Chemistry 2010; 6 (4) . https://dx.doi.org/10.2174/1573406411006040247
DOI https://dx.doi.org/10.2174/1573406411006040247 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Angiogenesis-regulating microRNAs and Ischemic Stroke
Current Vascular Pharmacology Disease-Modifying Agents in the Treatment of Multiple Sclerosis: A Review of Long-Term Outcomes
CNS & Neurological Disorders - Drug Targets Vascular Endothelial Growth Factor Receptor 1, a Therapeutic Target in Cancer, Inflammation and Other Disorders
Current Medicinal Chemistry Modulation of Inflammatory Response Improves Myocardial Infarct Healing in Rats
Current Pharmaceutical Design May Adjuvant Therapy Play A Role for the Management of Renal Cell Carcinoma? A Review of Literature and Ongoing Trials
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Targets for the Management of Peripheral Nerve Injury- Induced Neuropathic Pain
CNS & Neurological Disorders - Drug Targets An Automatic Glioma Segmentation System Using a Multilevel Attention Pyramid Scene Parsing Network
Current Medical Imaging Current Understanding of Dietary Polyphenols and their Role in Health and Disease
Current Nutrition & Food Science The Developing Role of Neuregulin1 In Cardiac Regenerative Stem Cell Therapy
Current Pharmaceutical Design Pharmacogenomics of Cardiovascular Complications in Diabetes and Obesity
Recent Patents on Biotechnology Design of Lipophilic Prodrugs to Improve Drug Delivery and Efficacy
Current Drug Targets Use of Peripheral Blood Stem Cells in Tissue Engineering
Current Tissue Engineering (Discontinued) Impact of N-acetylcysteine and Etodolac Treatment on Systolic and Diastolic Function in a Rat Model of Myocardial Steatosis Induced by High-Fat-Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets Receptor Fragments: Intracellular Signaling and Novel Therapeutic Targets
Current Hypertension Reviews Thiazide Diuretics: 50 Years and Beyond
Current Hypertension Reviews Calcium Sensitizers in Cardiac Surgery: Who, When, How and Why?
Current Vascular Pharmacology Hepatic Injury to the Newborn Liver Due to Drugs
Current Pharmaceutical Design Functional Roles of the Ca2+-activated K+ Channel, KCa3.1, in Brain Tumors
Current Neuropharmacology Clinically Relevant Reprogramming to Pluripotency
Recent Patents on Regenerative Medicine Epigenetic Drugs for Multiple Sclerosis
Current Neuropharmacology